This opportunity involves a requirement for a proteomics platform that measures over 5,400 human proteins simultaneously using Proximity Extension Assay technology. The system must work with only 2 microliters of plasma or serum and offer 99.5% specificity with a dynamic range of 10 orders of magnitude. The platform is intended for research on inflammation, microbiota, and cancer therapy. No specific budget amount, performance location, or non-bid timelines were provided in the description. The highly standardized, low-volume nature of the platform makes it suitable for epidemiology and multi-omics studies.